What is the next big thing for your company's portfolio?
To help pharmaceutical companies answer this question, Kaiser Associates conducted a comprehensive analysis of nearly every pharma R&D program in the world and compiled the findings into the Hot Indications List.
Our report includes:
- Kaiser's ranking and analysis of the Top 50 indications
- 4 Therapeutic Area Deep Dives
- Top 10 Emerging Orphan Diseases